Phibro Animal Health Corporation splits its revenue into 5 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Sep 30, 2026 was Medicated Feed Additives And Others at $206.5 million, 53% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q1 FY2027
Sep 30, 2026
|
Q4 FY2026
Jun 30, 2026
|
Q3 FY2026
Mar 31, 2026
|
Q2 FY2026
Dec 31, 2025
|
Q1 FY2026
Sep 30, 2025
|
Q4 FY2025
Jun 30, 2025
|
Q3 FY2025
Mar 31, 2025
|
Q2 FY2025
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,541
|
387
|
397
|
384
|
374
|
364
|
379
|
348
|
309
|
| Medicated Feed Additives And Others |
822
+12.0%
share 53.3%
|
206
+5.8%
share 53.4%
|
208
+0.5%
share 52.3%
|
206
+13.3%
share 53.7%
|
202
+34.4%
share 54.1%
|
195
share 53.6%
|
207
share 54.5%
|
182
share 52.2%
|
150
share 48.6%
|
| Mineral Nutrition |
293
+13.9%
share 19.0%
|
74
+16.8%
share 19.0%
|
77
+20.0%
share 19.4%
|
73
share 19.1%
|
69
share 18.4%
|
63
share 17.3%
|
64
share 16.9%
|
—
|
—
|
| Nutritional Specialties |
194
+5.0%
share 12.6%
|
47
-2.3%
share 12.2%
|
50
+5.3%
share 12.6%
|
47
+8.0%
share 12.2%
|
50
+9.4%
share 13.4%
|
48
share 13.2%
|
47
share 12.5%
|
43
share 12.5%
|
46
share 14.8%
|
| Vaccines |
156
+7.3%
share 10.1%
|
40
-1.5%
share 10.2%
|
40
+3.8%
share 10.1%
|
39
+15.7%
share 10.1%
|
38
+13.5%
share 10.1%
|
40
share 11.0%
|
39
share 10.2%
|
33
share 9.6%
|
33
share 10.7%
|
| Performance Products |
76
-3.2%
share 4.9%
|
20
+15.6%
share 5.2%
|
22
+0.6%
share 5.6%
|
19
-16.6%
share 4.9%
|
15
-9.7%
share 4.0%
|
17
share 4.8%
|
22
share 5.8%
|
23
share 6.5%
|
17
share 5.4%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PAHC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Teaneck, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1069899
- Former names
- PHILIPP BROTHERS CHEMICALS INC (until May 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.